Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
ApexOnco Front Page
Recent articles
The company will start its confirmatory bexobrutideg study in June.
An in vivo Car-T produced a 100% response rate – in three patients.
Rival BTK degraders face off, as do bispecific Cars and T-cell engagers.
Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.
Arcellx and AstraZeneca take centre stage.
Five years after settling, GSK is again accused of breaching the Jemperli deal.
Meanwhile, Zai Lab faces delays in its pivotal DLL3 trial.
